The research team is investigating administering exogenous surfactant in COVID-19 patients
with ARDS. The overall goal is to improve the outcome (mortality) of mechanically ventilated
COVID-19 patients. Although the investigators anticipate that clinical outcomes may improve
in the small group of patients receiving exogenous surfactant therapy in this small, single
center study, the primary goal is to first determine feasibility and safety.